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Transgenic sickle cell disease mice have high mortality and 
dysregulated immune responses after vaccination
Steven M. Szczepanek1, Eric R. Secor Jr2, Sonali J. Bracken2, Linda Guernsey2, Ektor 
Rafti2, Adam Matson2, Roger S. Thrall2, and Biree Andemariam1
1Adult Sickle Cell Center, Division of Hematology-Oncology, Lea Center for Hematologic 
Disorders, University of Connecticut Health Center, Farmington, CT
2Department of Immunology, University of Connecticut Health Center, Farmington, CT
Abstract
Background—Children with sickle cell disease (SCD) are susceptible to recurrent infections, 
which are often life threatening and necessitate frequent vaccinations. Given the altered baseline 
immunity and proinflammatory state associated with SCD, we sought to determine the relative 
safety and efficacy of vaccination in transgenic SCD mice.
Methods—Eight week-old SCD mice were vaccinated with ovalbumin (OVA) and aluminum 
hydroxide weekly for three weeks by the intraperitoneal (IP) or intramuscular (IM) route. One 
week after the third vaccination, serum cytokines/chemokines, immunoglobulins, and 
bronchoalveolar lavage (BAL) fluid cytokines were measured.
Results—Only SCD mice were prone to mortality associated with vaccination as 40% of the 
animals died after the IP vaccinations and 50% died after the IM vaccinations. Serum IgG2b and 
IgM were significantly lower in SCD than C57Bl/6 mice after vaccination, but OVA-specific IgE 
was significantly higher. Serum interleukin 1 alpha (IL-1α), IL-2, IL-5, macrophage inflammatory 
protein 1 alpha (MIP-1α), and granulocyte macrophage-colony stimulating factor (GM-CSF) were 
significantly lower in SCD mice than C57Bl/6 mice after vaccination, whereas BAL fluid IL-1β 
and IL-6 were elevated.
Conclusions—Mice with SCD appear to have a dysregulated immune response to vaccination. 
Thus, the relative safety and immunogenicity of vaccination should be studied in greater detail in 
the context of SCD.
INTRODUCTION
Children suffering from sickle cell disease (SCD) are prone to frequent and severe infections 
that can lead to premature death if prompt antibiotic treatment is not administered. One of 
the most common infections in children with SCD is caused by Streptococcus pneumoniae, 
which often manifests as pneumonia and can lead to septicemia if the bacterium becomes 
invasive. The incidence of invasive S. pneumoniae infection in individuals with SCD is 
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between 30–600 fold higher (depending on age) than what is observed in the general 
population (1). As a consequence, children with SCD typically adhere to strict vaccination 
schedules which often include more frequent booster shots than children without SCD. The 
introduction of pneumococcal vaccines has reduced the incidence of mortality associated 
with S. pneumoniae infection in children with SCD by 80–90% (2, 3); however, infection in 
vaccinees has nevertheless been reported in this population (4). Vaccination against both S. 
pneumoniae and Influenza A virus appear to result in low antigen-specific IgG and IgM 
antibody titers (5, 6), the latter of which is likely a function of a reduced number of IgM 
producing B-cells (7, 8). Furthermore, a recent study has shown an association between 
chronic transfusion of children with SCD and a lack of a protective post-vaccination 
antibody response to influenza A (9). Taken together, these findings bring into question the 
relative immunogenicity of vaccination in children with SCD when compared to control 
subjects and indicate that hypo-responsiveness to vaccine antigens may not be uncommon.
The phase one safety evaluations of vaccines are usually tested in the general population but 
are not tested in individuals with uncommon diseases such as SCD. The recently developed 
intranasal influenza vaccine (FluMist, MedImmune, Gaithersburg, MD) is one such example 
and, consequently, administration of this vaccine to SCD patients is not recommended by 
the CDC. Even when a vaccine is routinely administered as part of the standard vaccination 
schedule, such as is the case with the trivalent inactivated influenza (TIV) vaccine, 
controversy may arise pertaining to its safety in people with uncommon diseases. Indeed, 
recent retrospective studies using the vaccine safety datalink project have indicated that the 
TIV vaccine is not associated with hospitalization in children or adults with SCD (10, 11); 
however, a previous report by this group had shown that people with SCD had more 
frequent fever or pain episodes resulting in an inpatient visit within two weeks of influenza 
vaccination than control subjects (12). To our knowledge, no published prospective studies 
have been conducted in humans or mice to definitively determine if vaccination is associated 
with adverse effects in SCD.
Very little work has been conducted in transgenic SCD mice to study the effects of 
experimental treatment on basic outcomes that cannot be tested in humans. One of the few 
papers to do so demonstrated that NKT-cells are an important source of pulmonary 
dysfunction at baseline in NY1DD SCD mice (13). Another report used intraperitoneal (IP) 
injection of lipopolysaccharide (LPS) into the “Berkeley” (Berk) transgenic SCD mouse 
strain to determine the effects of systemic challenge with an inflammatory agent on markers 
of disease (14). Many of these mice died shortly after injection and the survivors exhibited 
negative respiratory outcomes and had increased inflammatory markers. In another study, 
experimental asthma was induced in SCD mice by subcutaneous (SC) implantation of 
ovalbumin (OVA), followed by OVA aerosol challenge (15). Mortality of SCD mice was 
associated with SC implantation of OVA, and marked increases in IgE was observed. A 
follow-up study by the same group also demonstrated increases in bronchoalveolar lavage 
(BAL) cytokines (including IL-1β and IL-6) after the induction of asthma in SCD mice (16). 
Taken together, these findings indicate that SCD results in exaggerated inflammatory 
responses in reaction to antigenic stimuli.
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There appears to be a dichotomy in SCD between hypo-responsiveness to some antigens and 
an overzealous inflammatory response to others. Our original goal was to study asthma in a 
murine model of SCD using our previously published IP OVA/Alum vaccination/
sensitization protocol (17). However, upon experiencing approximately 50% mortality with 
sensitization alone in multiple experiments, we shifted focus to understand how transgenic 
SCD mice respond to vaccination. Herein, we describe changes in systemic and pulmonary 
cytokines, serum antibodies, and antigen-specific IgE responses in SCD mice surviving 
vaccination as compared with wild-type and hemizygous mice. Implications for infection 
and vaccination in children with SCD are discussed.
RESULTS
Vaccination-Induced Mortality
IP vaccination of SCD mice with the protein antigen OVA and adjuvant alum resulted in 
significant mortality (40%) when compared to either C57Bl/6 or hemizygous (no deaths in 
either group; p<0.05; Figure 1). This effect occurred with increasing frequency at each 
additional IP injection. In order to validate that the route of inoculation was not the major 
factor of SCD mouse mortality, additional mice were inoculated with OVA/alum via the IM 
route. Again, only SCD mice died after the injections (50%), which was significantly 
different from C57Bl/6 and hemizygous mice. Interestingly, the kinetics of mortality were 
different between the two routes of inoculation, with IP resulting in the greatest mortality 
after the third vaccination and IM only resulting in mortality after one vaccination.
Antibody Responses
Concentrations of post-vaccination serum immunoglobulin class and sub-classes were 
measured one week after the third vaccination using a Luminex assay. When compared to 
C57Bl/6 mice, SCD mice exhibited significantly lower serum concentrations of IgG2b 
(Figure 2A). Serum concentrations of IgM were also significantly reduced in SCD mice. No 
differences were observed in any post-vaccination Ig class/sub-class between SCD and 
hemizygous mice. When comparing pre- versus post- vaccination serum antibody levels, 
dramatically higher fold-change increases were observed for IgG2b in C57Bl/6 mice than in 
SCD mice, indicating that the lower level of this Ig sub-class post-vaccination is attributable 
to an inability of SCD mice to produce it in response to vaccination (Figure 2B). No 
difference in the fold-change of IgM concentrations in the pre- versus post-vaccination 
samples was observed among the groups (Figure 2B), which is likely attributed to the 
previously reported reduction of IgM at baseline in SCD mice (8). When compared with 
C57Bl/6 mice, SCD mice exhibited dramatically increased OVA-specific IgE titers after 
vaccination (Figure 2C), indicating that SCD mice may be more prone to allergic 
sensitization than C57Bl/6 mice. No difference was observed in OVA-specific IgE titers 
when SCD and hemizygous mice were compared.
Cytokine/Chemokine Responses
Concentrations of post-vaccination serum cytokines and chemokines were measured one 
week after the third vaccination using a Luminex assay. When compared to C57Bl/6 mice, 
SCD mice had lower serum concentrations of the cytokines IL-1α, IL-2, and IL-5 (Figure 
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3A). Reduced concentrations of serum chemokines MIP-1α and GM-CSF were also found. 
No significant differences in the aforementioned cytokines/chemokines were measured 
between SCD and hemizygous mice. When comparing pre- versus post-vaccination cytokine 
levels, fold-change differences in IL-1α were not noticeably different among the groups 
(Figure 3B), which is likely attributed to the previously reported reduction of this cytokine at 
baseline in SCD mice (8). Dramatically higher pre- versus post-vaccination fold-change 
increases were observed for both IL-2 and GM-CSF in C57Bl/6 mice than SCD mice, 
indicating that the lower levels of these cytokines post-vaccination is attributed to an 
inability of SCD mice to produce them in response to vaccination. Moreover, when pre- 
versus post-vaccination titers were compared, SCD mice exhibited reduced levels of 
MIP-1α. This indicates that SCD has a severely dysregulated MIP-1α response after 
vaccination.
Several serum cytokines were significantly increased in response to vaccination in C57Bl/6 
mice, but not in SCD or hemizygous mice (Figure 3C). These cytokines include IL-1β, IL-7, 
IL-12(p70), and IL-17. These cytokines exhibited more variability within groups, thereby 
contributing to a lack of significance when post-vaccination concentrations were compared. 
However, SCD mice (and hemizygous) appear to have a reduced ability to produce these 
cytokines in response to vaccination. Taken together, SCD mice that survive inoculation 
appear to be hypo-responsive to vaccination, as demonstrated by their lack of cytokine 
production in serum post-vaccination.
In contrast to the hypo-responsiveness exhibited by SCD mice in the production of serum 
cytokines after vaccination, cytokines in BAL fluid appeared to be higher in SCD mice 
(Figure 4). BAL fluid IL-1β was not measurable in C57Bl/6 mice post-vaccination (MDL = 
0.20 pg/ml) and was significantly higher in SCD mice when compared with either 
hemizygous mice or C57Bl/6 mice. Similarly, IL-6 was elevated in the BAL fluid of SCD 
mice when compared with C57Bl/6 mice (not measurable, MDL = 0.28 pg/ml) after 
vaccination. No differences in post-vaccination BAL fluid IL-6 were observed between 
hemizygous mice and SCD mice.
DISCUSSION
Relative safety and immunogenicity are important features to consider when administering 
vaccines, yet these two basic parameters are not well-understood in children with 
uncommon diseases such as SCD. Death of SCD mice after injection of inflammatory agents 
is a phenomenon that has been known for some time and is presumably associated with 
heightened baseline inflammation. A previous study showed that IP inoculation with the 
proinflammatory molecule LPS resulted in approximately 60% mortality of SCD mice, 
whereas sham inoculation with saline had no effect (14). Protein antigens may also produce 
mortality in SCD mice, as has been shown by SC implantation of OVA (15). Our findings of 
approximately 40% mortality in SCD mice after IP OVA/alum injection and 50% mortality 
after IM OVA/alum injection correlate with these previous reports. Thus, our model of 
vaccination has clinical implications pertaining to possible adverse events associated with 
vaccination of children with SCD.
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The gold standard of immunogenicity for most vaccines is elicitation of the production of 
antigen-specific serum antibodies. As previously mentioned, SCD mice that survived 
vaccination had significantly higher OVA-specific IgE antibody serum concentrations than 
C57Bl/6 mice, indicating that these animals may be especially prone to allergic 
sensitization. Conversely, these same mice were hypo-responsive in terms of IgG2b and 
IgM production after vaccination. All groups of mice increased their IgM titers 4-fold in 
response to vaccination, which indicates that differences in post-vaccination IgM 
concentrations are due to low baseline production of this immunoglobulin. However, SCD 
mice only induced a 4-fold increase in IgG2b after vaccination, whereas C57Bl/6 mice 
increased serum concentrations more than 10-fold. The inability of SCD mice to induce 
wild-type levels of IgG2b antibodies has potential clinical implications as murine IgG2b is 
similar to human IgG3 (and to some degree IgG1) (18), with the ability to fix complement 
and bind to protein antigens. It is crucially important for vaccines to induce these functions 
for maximum efficacy. These findingsare also in line with the observation that children 
living with SCD have diminished antibody responses to the hepatitis B vaccine (19). Taken 
together, these findings have translational implications that should be investigated further in 
children living with SCD.
The ability of lymphocytes to become activated and proliferate in response to stimuli is 
essential for vaccine immunogenicity. Cytokines such as IL-2, IL-7, and IL-12 are 
responsible for allowing lymphocytes to mature/differentiate, proliferate, and generate 
immunological memory. The reduced post-vaccination serum concentrations and apparent 
inability of these cytokines to be sufficiently stimulated after vaccination indicate that 
lymphocytes in SCD mice surviving vaccination may have sub-par effector and memory 
functions. Furthermore, chemokines MIP-1α and GM-CSF, which are important for 
stimulating (20) and mobilizing (21) antigen presenting cells (APCs) in response to antigen, 
are not produced at wildtype levels by SCD mice following vaccination. In fact, MIP-1α 
appears to be down-regulated in response to vaccination in SCD mice. This has serious 
implications as MIP-1α is important for mobilization of DC precursors into the blood (22). 
MIP-1α is also a ligand for CCR5, which has been shown to be important for protection 
from pathogens such as influenza (23). Furthermore, it has been reported that there is a 
higher proportion of SCD patients in Brazil that also have the CCR5D32 mutant allele when 
compared to controls (24). Extrapolation of our results from the mouse model then indicates 
that these individuals may mount suboptimal immune responses to vaccination which may 
then leave them more susceptible to infection. SCD mice are also hypo-responsive to IL-17 
production post-vaccination and this cytokine is important for clearance of mucosal bacterial 
pathogens. Indeed, protection of mice from S. pneumoniae colonization appears to be IL-17-
dependent (25), which suggests that lack of IL-17 production in SCD mice may contribute to 
their increased susceptibility to pneumococcal infection (26).
Mouse models of acute lung injury are associated with increased levels of TNF-α, IL-1β, 
and IL-6 in BAL fluid. This milieu has been shown to increase the production of secretory 
IgA in the lungs to help protect from infection when the natural barrier defenses are 
weakened (27). SCD mice that survived vaccination had significantly elevated IL-1β and 
IL-6 in their BAL fluid one week after the third vaccination when compared with C57Bl/6 
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mice, indicating that lung injury associated with vaccination had occurred. Given the long-
elapsed time between inoculation and measurement of these cytokines, it would not be 
surprising if they were in fact higher in concentration in the lung airways at earlier time 
points. It would also not be surprising if TNF-α is elevated early on as well. A study of 
acute lung injury in SCD mice also showed increased IL-6 in BAL fluid within hours of LPS 
injection (14), which corroborates our findings. The finding of increased IL-1β in BAL fluid 
of SCD mice that survived vaccination also has clinical implications, as this cytokine has 
been associated with ischemic reperfusion injury in human SCD (28), which is also 
associated with acute chest syndrome. Thus, therapeutics targeting IL-6 and IL-1β may help 
to reduce pulmonary-related morbidity and mortality in people living with SCD.
Vaccination-related death of SCD mice raises the question by what mechanism these 
animals are dying. This study does not directly address this question, as all outcomes were 
measured one week after the third vaccination only in animals that tolerated the OVA/alum 
inoculation. However, we were able to determine that the SCD mice that tolerated IP 
vaccination had similarly high levels of antigen-specific serum IgE as the hemizygous 
controls, which were much higher than those found in C57Bl/6 mice. This raises the 
possibility that the sensitive SCD mice may have had even higher IgE levels and died of 
shock from a type I hypersensitivity reaction. Anecdotal support of this hypothesis comes 
from the observation that all SCD mice that died after vaccination were found dead within 
hours of OVA/alum injection. Furthermore, all but one SCD mouse died after the second or 
third IP injection, indicating that the mice had to be first sensitized to OVA/alum before they 
became susceptible to death from vaccination. Interestingly, susceptible SCD mice that were 
inoculated by the IM route all died after the first vaccination, indicating that these mice did 
not have to be sensitized to antigen to be susceptible to death associated with this route of 
vaccination. It therefore seems likely that these animals died from an exaggerated 
inflammatory response, possibly driven by the presence of the adjuvant alum. While we do 
not know the cause of vaccination-related death of SCD mice, it is likely a combination of 
multiple etiologies which may include both hypersensitivity reactions and exaggerated 
inflammatory responses. Further work is needed in order to more definitively answer this 
question.
Many studies have shown that both humans and mice with SCD live in an immunologically 
altered state. The study presented herein demonstrates that SCD mice are prone to death 
associated with vaccination, which is likely linked to the altered baseline immunity observed 
in these animals. Consequently, animals that survive inoculation appear to have dysregulated 
systemic immune responses to vaccination. Enhanced pulmonary production of IL-1β and 
IL-6 suggests acute lung injury may develop as a consequence of antigenic challenge. Our 
data suggest that the relative safety and immunogenicity of vaccination should be studied in 
greater detail in the context of SCD. Although it is clear that humans with SCD do not suffer 
mortality as a consequence of vaccination, there may be subclinical deleterious 
consequences that warrant further investigation.
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Animals used in this study have been previously described (8). Briefly, female mice, 
approximately 8 weeks old, weighing 15–25 g each, were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Berkeley sickle cell transgenic mice (Tg(Hu-
miniLCRα1GγAγδβS) Hba−/− Hbb−/−) expressing human HBA and HBBS and no longer 
expressing mouse Hba and Hbb were used as a murine model of SCD. The stock 
background of this strain is a mixture of FVB/N, 129, DBA/2, Black Swiss and >50% 
C57Bl/6 genomes. It was backcrossed to C57Bl/6 one generation after importation to The 
Jackson Laboratory. Hemizygous controls of the Berkeley transgenic SCD mouse (generated 
on the same mixed background of strains) that express no mouse Hba, but do express one 
copy of mouse Hbb, human HBA and HBBS giving rise to a hemizygous genotype were used 
as a second control arm. All mice were conventionally housed in plastic cages with corncob 
bedding. The housing facility was maintained at 22–24°C with a 12 hr light/dark cycle. 
Chow and water were given ad libitum. The Animal Care Committee at the University of 
Connecticut Health Center approved all mouse experiments.
Vaccinations
Mice were vaccinated by either the intraperitoneal (IP) or intramuscular (IM) route once per 
week for three weeks. A suspension of 25 μg of OVA (grade V, Sigma Chemical, St. Louis, 
MO) with 2 mg of aluminum hydroxide (alum) in 500 μl of saline was used for IP 
inoculations, while a final volume of 50 μl was used for IM inoculations (one ½ dose 
injection into each hindlimb).
Collection of Serum and BAL fluid
One week after the third injection, mice were humanely euthanized with an overdose of 
ketamine/xylazine and whole blood was immediately collected via cardiac puncture and 
placed into non-heparinized tubes for serum purification. Blood was allowed to clot at room 
temperature for approximately 30–60 min and then spun for 10 min at 4000 RPM in an 
Eppendorf 5415 C centrifuge. Serum was then aliquoted and stored at −80°C until used. 
After sacrifice, a bronchoalveolar lavage (BAL) was performed on mouse lungs with five 1-
ml aliquots of physiologic saline. The BAL was then centrifuged at 1700 × g using a 
Thermo Scientific Sorvall ST 40R centrifuge with a swinging bucket rotor and the 
supernatant (BAL fluid) was removed and concentrated 10x using Amicon Centriplus 
YM-10 filtration devices (Millipore, Bedford, MA), per the manufacturer’s instructions. 
BAL fluid samples were stored at −80°C until used.
Analysis of Cytokines and Antibodies using Luminex Assays
Analysis of serum chemokines/cytokines and antibody class/sub-class were conducted using 
Milliplex kits (Millipore), as previously described (8). Cytokines were analyzed using a 1:2 
dilution while immunoglobulins were analyzed at a 1:25,000 dilution (concentrations were 
adjusted to account for dilution). Serum IgA fell below the detection limit at this dilution for 
all animals and was not considered for analysis. BAL fluid cytokines were processed and 
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analyzed using the same technique as serum, but sterile PBS was used as a diluent for the 
standard curve. For samples in which an analyte could not be detected above the minimum 
detection limit (MDL) surrogate values of 0.1 or 1 less than the MDL (depending on the 
number of significant figures used) were used. For BAL fluid samples, post-assay sample 
concentration and limits of detection were reported taking into consideration the 10X sample 
concentration prior to analysis. Fold-change values were calculated using data from naïve 
animals published in a previous report (8). Calculations are based on groups of 11 C57Bl/6 
mice, 11 hemizygous mice, and 9 SCD mice.
OVA-specific Serum IgE Levels
An OVA-specific sandwich ELISA was used to measure serum levels of IgE, as has been 
previously described (29). Results were interpolated from a standard curve. Calculations are 
based on groups of 8 C57Bl/6 mice, 9 hemizygous mice, and 8 SCD mice.
Statistics
Statistical comparisons between groups were made with one-way analysis of variance and 
pairwise comparisons were conducted utilizing the Dunnett’s post-hoc test with SCD 
serving as the control group. Analyses were conducted using GraphPad Prism version 5 
software (GraphPad software, San Diego, CA) unless no variance was recorded within a 
group, then JMP statistical software version 5.1 (SAS Institute, Cary, NC) was used. All 
data were expressed as means +/− standard error of the mean. Differences were considered 
significant if p ≤ 0.05.
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Post-vaccination Kaplan-Meier survival curves. (A) Percent survival of C57Bl/6 (n=11), 
hemizygous (n=11), or SCD mice (n=15) after each IP vaccination. (B) Percent survival of 
C57Bl/6 (n=6), hemizygous (n=7), or SCD mice (n=6) after each IM vaccination. Curves for 
SCD mice for both routes of inoculation were significantly different from C57Bl/6 and 
hemizyous mice (p<0.05). Squares = C57Bl6 and hemizygous mice; triangle = SCD.
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Serum antibody responses to vaccination. (A) Significantly different serum immunoglobulin 
concentrations post-vaccination as measured by Luminex assay (IgG2b: C57Bl/6 = 
3.88×106 ng/ml (SEM, 2,072,000), hemizygous = 350,000 ng/ml (SEM, 92,000), SCD = 
635,000 ng/ml (SEM, 162,000); p<0.01) (IgM: C57Bl/6 = 1.44×106 ng/ml (SEM, 244,000), 
hemizygous = 497,000 ng/ml (SEM, 59,000), SCD = 570,000 ng/ml (SEM, 75,000); 
p<0.001). (B) Pre- versus postvaccination fold-change in significantly different serum 
immunoglobulins postvaccination. (C) Serum concentrations of OVA-specific IgE 
antibodies as measured by ELISA (C57Bl/6 = 242 ng/ml (SEM, 48), hemizygous = 1854 
ng/ml (SEM, 758), SCD = 2452 ng/ml (SEM, 754); p<0.05). Bars represent mean levels +/− 
standard error of the mean. Significant differences were determined by one-way analysis of 
variance and pairwise comparisons were conducted using the Dunnett’s post-hoc test with 
SCD serving as the control group. Black bars = C57Bl/6; grey bars = hemizygous; white 
bars = SCD. *p<0.05, **p<0.01.
Szczepanek et al. Page 12










Serum cytokine and chemokine responses to vaccination. (A) Significantly different 
postvaccination cytokine/chemokine serum concentrations as measured by Luminex assay 
(IL-1α: C57Bl/6 = 2692 pg/ml (SEM, 659), hemizygous = 1224 pg/ml (SEM, 236), SCD = 
195 pg/ml (SEM, 64); p<0.001) (IL-2: C57Bl/6 = 55 pg/ml (SEM, 28), hemizygous = 4.2 
pg/ml (SEM, 1.4), SCD = 5.8 pg/ml (SEM, 3.2); p<0.05) (IL-5: C57Bl/6 = 54 (SEM, 8.7), 
hemizygous = 31 pg/ml (SEM, 5.8), SCD = 27 pg/ml (SEM, 5.2); p<0.05) (MIP-1α: 
C57Bl/6 = 53 pg/ml (SEM, 16), hemizygous = 15 pg/ml (SEM, 4.9), SCD = 19 pg/ml (SEM, 
8.8); p<0.05) (GM-CSF: C57Bl/6 = 89 pg/ml (SEM, 31), hemizygous = 5.5 pg/ml (SEM, 
NA), SCD = 10 pg/ml (SEM, 4.7); p<0.01). (B) Pre- versus post-vaccination fold-change in 
significantly different post-vaccination serum cytokines/chemokines. (C) Fold-change in 
serum cytokines that were only significantly different pre- versus post-vaccination in 
C57Bl/6 mice. Bars represent mean levels +/− standard error of the mean. Significant 
differences were determined by one-way analysis of variance and pairwise comparisons 
were conducted using the Dunnett’s post-hoc test with SCD serving as the control group. 
Black bars = C57Bl/6; grey bars = hemizygous; white bars = SCD. *p<0.05, **p<0.01.
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BAL fluid cytokines measured in response to vaccination. No cytokines were detected above 
the MDL before vaccination (IL-1β: C57Bl/6 < 0.20 pg/ml, hemizygous = 1.8 pg/ml (SEM, 
1.1), SCD = 11 pg/ml (SEM, 4.9); p<0.05) (IL-6: C57Bl/6 < 0.28 pg/ml, hemizygous = 6.5 
pg/ml (SEM, 3.5), SCD = 17 pg/l (SEM, 5.9); p<0.05). Bars represent mean levels +/− 
standard error of the mean. Significant differences were determined by one-way analysis of 
variance and pairwise comparisons were conducted utilizing the Dunnett’s post-hoc test with 
SCD serving as the control group. Black bars = C57Bl/6; grey bars = hemizygous; white 
bars = SCD. *p<0.05
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